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Apolipoprotein E Polymorphism and Neuropsychological Outcome 
following Subarachnoid Haemorrhage 
 
Abstract 
Objectives - To investigate the association between APOE genotype and cognitive and 
emotional outcome following spontaneous subarachnoid haemorrhage (SAH). 
 
Materials and Methods - Neuropsychological assessments were conducted with 70 SAH 
survivors derived from a consecutive series of neurosurgical admissions. Outcomes, 
including cognitive tests, health questionnaires and Glasgow Outcome Scale at a mean of 
16 months after SAH, were compared with presence or absence of the ε4 allele. 
 
Results – There was no evidence that SAH survivors possessing the ε4 allele had poorer 
outcome. The only suggestion of an association between the ε4 allele and outcome was in 
a subgroup of patients with a Fisher Grade 4 haemorrhage, though this trend did not 
reach statistical significance. 
 
Conclusions – Overall, possession of the APOE ε4 allele is not significantly associated 
with neuropsychological outcome following subarachnoid haemorrhage. However there 
may be an effect amongst those with a Fisher Grade 4 haemorrhage. 
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 Introduction 
Several studies have suggested that polymorphism of the Apolipoprotein E (APOE) gene 
influences recovery from brain injury, with the ε4 allele associated with poorer outcome. 
Nicoll and colleagues first reported altered neuropathological findings amongst ε4 patients 
who suffered fatal head injury (1).  Other studies of outcome following head injury have 
indicated poorer recovery amongst those with the ε4 allele. The first prospective clinical study 
reported that ε4 patients were more than twice as likely to have a poor outcome as determined 
by the Glasgow Outcome Scale (2). Poorer outcome in ε4 survivors of head injury has also 
been reported amongst brain injury patients who have participated in rehabilitation 
programmes (3, 4). 
 
These findings have been reflected by studies of outcome following intracerebral 
haemorrhage, in which patients with ε4 alleles were more likely to die or to have a poor 
outcome if they survived than were non-ε4 patients (5, 6). However this apparently deleterious 
effect of the ε4 allele has not been reported in outcome studies of ischaemic stroke (6, 7), 
suggesting that the effect may be influenced by the type of brain insult. 
 
Recent studies of the association between the apolipoprotein E gene and outcome following 
subarachnoid haemorrhage have reported conflicting findings. Two studies, one prospective 
and the other retrospective, have found significantly poorer outcome in patients with the ε4 
allele (8, 9), whilst a prospective study involving 100 SAH patients found no association 
between APOE genotype and outcome (10). However these studies have been limited by the 
use of a relatively simple categorisation of death or disability as the sole measure of outcome. 
 
  
The current study reports the results of a detailed neuropsychological assessment of outcome 
in 70 patients derived from a consecutive series of neurosurgical admissions with suspected 
SAH.  A comparison of the current study with previous studies that have reported an 
association between the є4 allele and outcome following brain injury is given in Table 1. 
 
<Insert Table 1 around here> 
(2-9) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Material and Methods 
Patients: From a consecutive series of 125 neurosurgical admissions with suspected SAH, 19 
died as a consequence of the haemorrhage, 12 did not have SAH confirmed by CT or lumbar 
puncture, one was excluded due to a previously clipped aneurysm and nine did not consent to 
the earlier part of the study (10). The remaining 84 patients were contacted by letter and asked 
to participate in the neuropsychological assessment. Of these patients, no contact could be 
established with seven, six either declined to participate or repeatedly did not attend arranged 
appointments and one lived too far from the unit to travel. The remaining 70 patients 
participated in the neuropsychological assessment either in their own homes or at the 
neurosurgical unit depending on their preference. The study was approved by the local ethics 
committee and informed consent was obtained from all patients prior to the assessment. 
 
Clinical indices for the 70 participating patients and the 14 non-participants are outlined in 
Table 2. There were no significant differences between participants and non-participants. Of 
those who participated in the neuropsychological assessment (N = 70, 43 females), the mean 
age was 45.2 years (SD 15.2) with a range from 25 to 74 years. Mean years of education was 
12.21 (SD 2.1) ranging from 9 to 19 years. Mean time between initial admission to the 
neurosurgical unit and neuropsychological assessment was 16.3 months (SD 2.1) with a range 
from 14 to 23 months. The majority (80%) of patients were married or in a stable cohabiting 
relationship. 
 
<Insert Table 2 around here> 
 
 
 APOE genotypes were determined using polymerase chain reaction as described previously 
(10, 11). All assessments and scoring were conducted blind to genotype. 
 
Neuropsychological Assessment  
The neuropsychological interview involved the assessment of cognitive performance, 
including measures of visual and verbal memory, information processing, attention and 
executive functioning. The extended Glasgow Outcome Scale (GOS) was completed as part of 
a semistructured interview. Questionnaire measures of emotional and functional outcome 
were given and explained to patients to be returned by post. An overview of the assessment 
employed is given in Table 3. 
 
<Insert Table 3 around here> 
(12-24) 
 
There were no notable differences between ε4 and non-ε4 patients in terms of educational 
level or social class. There was a slight difference in mean age at assessment (ε4 52.1 vs non-
ε4 48.2) which was not statistically significant. In order to control for any possible influences 
of this slight age difference, the relationship between the APOE ε4 allele (present or absent) 
and cognitive task performance was determined using analysis of covariance, with age at 
assessment entered as co-variate. The relationship between the ε4 allele and measures of 
emotional and functional outcome was determined using non-parametric Mann-Whitney tests. 
 
 
 
 Results 
The APOE ε4 allele was present in 16 (23%) of the 70 patients who participated in 
assessments at 14 months. There were no significant differences between ε4 and non-ε4 
patients in terms of aneurysmal origin (ε4 88% vs non-ε4 81%), anterior communicating 
artery aneurysm (ε4 25% vs non-ε4 28%), or admission World Federation of Neurological 
Surgeons (WFNS) grade (grade I: ε4 63% vs. non-ε4 70%).  A Fisher Grade of 4 was more 
common amongst ε4 patients, with six (38%) of sixteen ε4 patients having a Fisher Grade 4 
relative to fourteen (26%) of fifty-four non-ε4 patients, though this difference did not reach 
statistical significance. None of the sixteen ε4 patients had an intraparenchymal haematoma, 
whereas haematoma was present in ten of the non-ε4 patients. The Fisher Grade 4 ε4 patients 
all had intraventricular haemorrhages. 
 
< Insert Table 4 around here >  
 
As shown in Table 4, there were no consistent associations between presence of the ε4 allele 
and performance on the neuropsychological measures. The WAIS comprehension task 
difference was the only difference to be statistically significant at the p < 0.05 level, with this 
difference in the opposite direction to that expected and no longer significant after Bonferroni 
correction. Possession of the ε4 allele was not associated with the presence of anxiety or 
depression amongst patients and there were no differences in outcome assessed using the GOS 
or SF-36. There was also no association between presence of the ε4 allele and change in GOS 
between assessments at 6 & 16 months. 
 
 There was a suggestion of an interaction between the ε4 allele and Fisher Grade. Only one 
(17%) of the six ε4 Fisher 4 patients improved on GOS, relative to 6 (43%) of 14 non-ε4 
Fisher 4 patients. At the 16 month assessment four (67%) of the six ε4 Fisher 4 patients 
remained severely disabled relative to five (36%) of fourteen non-ε4 Fisher 4 patients. By 
contrast amongst patients with Fisher Grades 1-3, none of the ten ε4, and only two of the forty 
non-ε4 patients were severely disabled at 16 months. There was also a non-significant trend 
for the ε4 Fisher 4 patients to perform more poorly than non-ε4 Fisher 4 patients on verbal 
memory tasks such as logical memory and verbal paired associates (Table 5).  
 
<Insert Table 5 around here > 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Discussion 
Previous studies investigating the association between APOE genotype and recovery from 
stroke have used relatively crude indices of outcome, but have generally found poorer 
outcome amongst ε4 ICH patients, with little if any effect of the ε4 allele upon outcome 
following ischaemic stroke (5-7). Additionally, evidence suggests that the ε4 allele has an 
independent rather than a synergistic influence upon the risk of cognitive decline or dementia 
following stroke (25). Recent studies have reported conflicting findings in relation to the 
association between ε4 and outcome following SAH (8-10). 
 
The current study reports findings from a detailed neuropsychological assessment of SAH 
survivors which did not identify an association between the ε4 allele and outcome amongst 
patients in whom haemorrhage was confined to the subarachnoid space (Fisher Grades 1-3). 
There were however suggestions of an effect of the ε4 allele upon outcome and verbal 
memory amongst Fisher Grade 4 patients, in whom haemorrhage extended into the ventricles 
or brain parenchyma. These Fisher 4 patients might be viewed as having more in common 
with intracerebral haemorrhage patients than do the lower Fisher Grade patients and thus it 
might be expected that they would be more likely to demonstrate an effect of the ε4 allele.  
 
It is possible that the ε4 patients were disposed towards greater severity of haemorrhage, 
which resulted in a greater proportion of them having a Fisher Grade 4. Evidence from the 
acute stage of this patient cohort suggested that ε4 patients may be less susceptible to 
vasospasm but more susceptible to re-haemorrhage (10). This would be consistent with 
findings of an association between ε4 and recovery from ICH but not ischaemic stroke (5-7).  
 The suggestions of greater initial haemorrhage and risk of re-haemorrhage amongst ε4 patients 
are also consistent with emerging evidence suggesting that ε4 individuals may have deficient 
blood clotting mechanisms and larger haematoma volumes (26, 27). 
 
Alternatively it is possible that greater secondary damage occurs amongst Fisher 4 ε4 patients 
following subarachnoid haemorrhage. Previous studies have demonstrated that the cytotoxic 
effects of amyloid β-protein (Aβ) may be mediated by oxidative damage (28, 29). Aβ deposits 
are more likely to be present in the vessels of APOE ε4 carriers and may increase oxidative 
damage following haemorrhage, particularly amongst Fisher 4 patients in whom extravascular 
blood is present in the parenchyma or ventricles. However the current findings indicate that 
the ε4 allele is not an important factor in the neuropsychological outcome of those who 
survive the initial haemorrhage when all patients are considered as a group. Earlier findings of 
an association between the ε4 allele and outcome were limited by their use of a relatively 
simple scale of death / disability as their sole outcome measure and as such may reflect an 
association with survival rather than functional outcome following SAH.  
 
In summary, the current study does not find an overall association between the APOE ε4 allele 
and neuropsychological outcome following SAH. However, the study raises the possibility 
that the presence of ε4 may be associated with outcome in a subgroup with Fisher Grade 4. 
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Table 1. Studies comparing APOE genotype with outcome following brain injury 
Study N Patient Group Outcome Measures 
Teasdale G. et al (2)  89 * Head Injury GOS 
Lichtman (3)    31  Head Injury Telephone FIM 
Friedman (4)    69       Head Injury Clinician determined outcomes 
Alberts M J (5)  44 *            ICH Bartel index 
McCarron et al (6)  69 *            ICH Return Home vs In care or Death 
Catto et al (7) 592 *      Acute stroke Mortality 
Leung et al (8) 72 * SAH GOS 
Niskakangas et al (9) 108 * SAH GOS 
Current Study    70 SAH 15 Neuropsychological tasks,  
4 Emotional outcome measures, 
Extended GOS  
 
GOS: Glasgow Outcome Scale; FIM: Functional Independence Measure; ICH: Intracerebral Haemorrhage;  
SAH: Subarachnoid Haemorrhage 
*:  Includes deceased patients 
 
 
 
 
 
 
  
 Table 2: Clinical Variables.  Number of cases (with percentage in parentheses) 
 Participants Non-
Participants 
 Participants Non-
Participants 
Fisher Grade 0 1   (  1.4) 0 WFNS Grade I 47  (67.1) 10 (71.4) 
Fisher Grade I 6   (  8.6)  2  (14.3) WFNS Grade II 12  (17.1)  2  (14.3) 
Fisher Grade II 6   (  8.6) 0 WFNS Grade III 2   (  2.9) 0 
Fisher Grade III 37   (52.9)  6  ( 42.9) WFNS Grade IV 3   (  4.3) 0 
Fisher Grade IV 20   (28.5)  6  ( 42.9) WFNS Grade V 6   (  8.6)  2  (14.3) 
      
No Clinical Deterioration 50  (71.4) 10 (71.4) Aneurysmal SAH 56 (80.0) 12 (85.7) 
Deteriorated Once 7  (10.0)  2  (14.3) Negative Angio † 12 (17.1) 2 (14.3) 
More than Once 13  (18.6)  2  (14.3)    
      
Surgical Intervention 54   (77.1) 12  (85.7) Haematoma  10 (14.3)  2  (14.3) 
No Surgery 16   (22.9)  2  (14.3) No Haematoma 60 (85.7) 12  (85.7) 
 
† : No angio performed for two of the participating patients  
 
 
 
 
 
 
 
 
 
 
 Table 3: Neuropsychological Assessment Battery 
 
Cognitive Tasks Global Outcome  
Digit Span - WAIS-R (12) Extended Glasgow Outcome Scale (13) 
Comprehension - WAIS-R (12) UK Short Form-36 Health Survey (SF-36) (14) 
Block Design - WAIS-R (12)  
Digit-Symbol  - WAIS-R (12)  
PASAT (2 and 4 second interval) (15) Emotional Outcome  
National Adult Reading Test (16) Hospital Anxiety and Depression Scale (17) 
McKenna Graded Naming Test (18) State Trait Anxiety Inventory (19) 
Logical Memory (20) Beck Depression Inventory (21) 
Verbal Paired Associates (20) General Health Questionnaire (22) 
Figural Memory WMS-R (20)  
Brixton Spatial Anticipation Test (23)  
Verbal Fluency ‘F’ ‘A’ ‘S’   
Rey-Osterreith Complex Figure   
Trail Making A & B   
Stroop Test: (24)  
 
 
 
 
 
 
 
 
 
 
 
 Table 4: APOE ε4 allele and Cognitive Performance 
 ε4 allele present No ε4 allele   
 Mean SD Mean SD F        p 
Digit Span 15.47 3.85 15.39 4.43 0.64 (1,65) 0.429 
Comprehension 19.93 3.94 18.22 6.07 4.68 (1,65) 0.034 * 
Block Design 22.00 9.74 22.56 9.59 0.98 (1,66) 0.326 
Digit Symbol 40.20 11.43 45.15 12.78 0.01 (1,63) 0.946 
PASAT 4 seconds 47.54 14.32 46.80 13.97 0.69 (1,55) 0.411 
PASAT 2 seconds 30.08 9.78 32.31 11.93 0.01 (1,47) 0.940 
GNT 20.07 5.66 19.81 5.60 0.94 (1,65) 0.337 
Logical Memory  22.93 7.71 23.56 8.40 0.31 (1,65) 0.579 
Delayed Logical Memory 17.43 11.03 18.83 8.82 0.11 (1,63) 0.741 
Paired Associates 15.36 5.21 16.00 4.75 0.04 (1,61) 0.845 
Delayed Associates 5.43 2.77 6.38 1.58 1.02 (1,58) 0.318 
Figural Memory 6.54 1.94 6.69 1.68 0.65 (1,60) 0.424 
Brixton Spatial † 22.36 6.42 19.54 8.66 0.22 (1,60) 0.642 
Verbal Fluency FAS 31.53 13.58 33.36 15.05 0.38 (1,64) 0.542 
Rey Copy 27.72 6.19 29.39 5.41 0.02 (1,62) 0.893 
Rey Immed Recall 11.47 9.62 14.45 7.49 0.12 (1,61) 0.727 
Trailmaking A † 54.93 33.31 42.28 19.22 1.39 (1,64) 0.242 
Trailmaking B † 95.31 30.24 87.59 38.77 0.14 (1,58) 0.709 
Stroop Interference 0.97 6.51 -0.74 6.54 1.14 (1,56) 0.291 
 
Analysis of covariance with age at assessment as co-variate 
† Denotes task in which higher score represents worse performance;    * p < 0.05  
  
  
 
 
Table 5: Mean Verbal Memory Performance in Fisher 4 Patients by ε4 allele  
(Standard deviation in parentheses) 
 
 
Verbal memory Task ε4 (n=6) Non-ε4 (n=14) 
Logical Memory   15.8 (5.9) 20.8 (8.6) 
Delayed Logical Memory  6.0 (6.7) 16.2 (9.1) 
Verbal Paired Associates 9.3 (3.3) 14.9 (4.8) 
Delayed Verbal Paired Associates 2.0 (1.2) 6.1 (1.5) 
 
 
 
 
 
 
 
 
 
